Manage New Warnings About Clarithromycin and Cardiovascular Risk

April 2018

You'll hear about an increased risk of CV events or death with clarithromycin.

A new FDA warning about this focuses on patients with coronary artery disease (CAD).

Macrolide antibiotics...clarithromycin, erythromycin, and azithromycin...already have warnings about QT prolongation and torsades.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote